Unknown

Dataset Information

0

Shiga-like toxin I exerts specific and potent anti-tumour efficacy against gastric cancer cell proliferation when driven by tumour-preferential Frizzled-7 promoter.


ABSTRACT:

Objectives

Tumour-targeted gene therapy is a promising approach for effective control of gastric cancer cell proliferation. Our study aims to develop a cancer therapy which combines tumour-targeting promoters with cytotoxins.

Methods

The expression of globotriaosylceramide (Gb3), which is a Shiga-like toxin I (Stx1) receptor, was verified in gastric cancer compared with normal stomach tissues as assessed by flow cytometry and immunohistochemical analysis. We therefore constructed the recombinant pFZD7-Stx1 plasmid vectors with tumour-preferential Frizzled-7 promoter and Stx1. pFZD7-Stx1 was used to treat gastric cancer in vitro and in vivo. The gastric cancer cell proliferation and tumour growth were identified after the transfection with the pFZD7-Stx1.

Results

Globotriaosylceramide was obviously increased in gastric cancer compared with normal stomach. The gastric cancer cell proliferation and tumour growth decreased significantly after the transfection with the pFZD7-Stx1.

Conclusion

Frizzled-7 promoter is preferentially active, and Gb3 is abundant in gastric cancer cells. Frizzled-7 promoter and Stx1 may be used to determine a novel and relatively specific and potent gastric cancer therapeutic strategy.

SUBMITTER: Xu H 

PROVIDER: S-EPMC6536451 | biostudies-literature | 2019 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Shiga-like toxin I exerts specific and potent anti-tumour efficacy against gastric cancer cell proliferation when driven by tumour-preferential Frizzled-7 promoter.

Xu Hongpan H   Peng Lijun L   Shen Mengjiao M   Xia Yanyan Y   Li Zhiyang Z   He Nongyue N  

Cell proliferation 20190406 3


<h4>Objectives</h4>Tumour-targeted gene therapy is a promising approach for effective control of gastric cancer cell proliferation. Our study aims to develop a cancer therapy which combines tumour-targeting promoters with cytotoxins.<h4>Methods</h4>The expression of globotriaosylceramide (Gb3), which is a Shiga-like toxin I (Stx1) receptor, was verified in gastric cancer compared with normal stomach tissues as assessed by flow cytometry and immunohistochemical analysis. We therefore constructed  ...[more]

Similar Datasets

| S-EPMC4741869 | biostudies-literature
| S-EPMC3579788 | biostudies-literature
| S-EPMC11633152 | biostudies-literature
| S-EPMC11804009 | biostudies-literature
2025-02-18 | PXD052925 | Pride
| S-EPMC3216503 | biostudies-literature
| S-EPMC6266700 | biostudies-literature
| PRJEB37181 | ENA
| S-EPMC3608586 | biostudies-literature
| S-EPMC2211750 | biostudies-literature